KINDSTAR GLOBAL (09960) has released its financial results for the six months ended June 30, 2026. During the period, the group generated revenue of 4.74 billion yuan, representing a year-on-year increase of 3.70%. Gross profit reached 2.18 billion yuan, up 10.9% from the prior year. The company recorded a loss attributable to owners of the parent amounting to 18.864 million yuan, with a basic loss per share of 1.89 cents.

The group attributed the revenue growth primarily to the stable performance of its core segments and the rapid expansion of its oncology testing division. Notably, the oncology testing segment benefited from deep synergies with acquired targets across channels, technology, and customer resources, delivering significant incremental contributions and establishing itself as a new growth engine. Meanwhile, the hematology testing segment, serving as the group's cornerstone, continued to demonstrate stability.

The improvement in gross margin was driven by revenue growth, the realization of acquisition synergies, and the group's ongoing efforts to optimize organizational structure and human resource allocation. Stringent cost control measures proved effective, with employee costs and other operating expenses declining by approximately 5.7% and 7.9% year-on-year, respectively. Raw material costs increased in line with business expansion, resulting in an overall optimized cost structure and steadily enhanced profitability.